# Clinical trial results:
# A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck.

## Summary

| | |
|---|---|
| EudraCT number | 2016-001794-32 |
| Trial protocol | FR |
| Global end of trial date | 20 October 2021 |

**Results information**

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 13 August 2022 |
| First version publication date | 13 August 2022 |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | UC-0130/1619 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03132038 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | Unicancer |
| Sponsor organisation address | 101 rue de Tolbiac, Paris, France, 75013 |
| Public contact | Nourredine AIT-RAHMOUNE, UNICANCER, 33 1 71 93 67 04, n.ait-rahmoune@unicancer.fr |
| Scientific contact | Nourredine AIT-RAHMOUNE, UNICANCER, 33 1 71 93 67 04, n.ait-rahmoune@unicancer.fr |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 30 September 2020 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 20 October 2021 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the non progression rate at 6 months.

Protection of trial subjects:

In order to ensure the protection of the rights, safety and well-being of trial subjects, this study was conducted in accordance with the ethical principles that have their origins in the latest version of the Declaration of Helsinki (1964) and subsequent amendments, ICH Good Clinical Practice Guidelines (CPMP/ICH/135/95), the European Directive (2001/20/CE) on the conduct of clinical trials and subsequent texts (Eudralex Vol 10), and the applicable local regulatory requirements and laws (The Huriet Law N°88-1138 of the 20th December 1998 on the protection of persons taking part in biomedical research; The National Informatics and Freedoms Commission – Law N° 78-17 of the 6th January 1978 modified by the law N° 2004-801 of the 6th August 2004 concerning the protection of the person with regards to the use of personal data; Bioethical law N°2011-814 of the 8th July 2011).
Furthermore, independent Ethics Committees reviewed and gave favorable opinions to the study documents, including the initial protocol and all subsequent amendments, and all information and documents provided to subjects/patients.
Written informed consent was obtained from all patients prior to enrollment.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 24 March 2017 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety, Efficacy |
| Long term follow-up duration | 2 Years |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | France: 98 |
| Worldwide total number of subjects | 98 |
| EEA total number of subjects | 98 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|---|---|
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 58 |
| From 65 to 84 years | 40 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

The NISCAHN study was a multicenter, open-label, non-controlled, phase II study in patients who were suffering from recurrent and/or metastatic Salivary Glands Carcinoma (SGC) not eligible to local treatment, who have progressed during the 6 months period before entering the study and were eligible for nivolumab monotherapy.

### Pre-assignment

Screening details:

The study consisted of a 28-day screening phase to establish patients' eligibility and document baseline measurements, a treatment phase (28-day cycle till disease progression - 12 cycles maximum), and a long-term follow-up to monitor the non-progression rate, progression-free survival, overall survival, and overall response rate.

### Period 1

| | |
|---|---|
| Period 1 title | overall period |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Adenoid cystic carcinoma (ACC) |

Arm description:

Salivary Glands Carcinoma were separated in two cohorts/sub-groups: Adenoid Cystic Carcinoma (ACC) and Non-Adenoid Cystic Carcinoma (Non ACC).
In this "Arm" we reported results from the ACC subgroup.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Nivolumab was given as a 60 minutes (± 5 minutes) intrvelous infusion at a fixed dose of 3 mg/kg every 2 weeks.

| | |
|---|---|
| **Arm title** | Non-Adenoid Cystic Carcinoma (Non ACC) |

Arm description:

Salivary Glands Carcinoma were separated in two cohorts/sub-groups: Adenoid Cystic Carcinoma (ACC) and Non-Adenoid Cystic Carcinoma (Non ACC).
In this "Arm" we reported results from the Non ACC subgroup.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Nivolumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Nivolumab was given as a 60 minutes (± 5 minutes) intrvelous infusion at a fixed dose of 3 mg/kg every 2 weeks.

| **Number of subjects in period 1** | Adenoid cystic carcinoma (ACC) | Non-Adenoid Cystic Carcinoma (Non ACC) |
|---|---|---|
| Started | 46 | 52 |
| Completed | 10 | 4 |
| Not completed | 36 | 48 |
| Physician decision | 1 | - |
| Patient decision | 1 | 2 |
| Disease progression | 29 | 41 |
| Adverse event, non-fatal | 5 | - |
| Death | - | 5 |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Adenoid cystic carcinoma (ACC) |
| Reporting group description: | |
| Salivary Glands Carcinoma were separated in two cohorts/sub-groups: Adenoid Cystic Carcinoma (ACC) and Non-Adenoid Cystic Carcinoma (Non ACC).<br>In this "Arm" we reported results from the ACC subgroup. | |
| Reporting group title | Non-Adenoid Cystic Carcinoma (Non ACC) |
| Reporting group description: | |
| Salivary Glands Carcinoma were separated in two cohorts/sub-groups: Adenoid Cystic Carcinoma (ACC) and Non-Adenoid Cystic Carcinoma (Non ACC).<br>In this "Arm" we reported results from the Non ACC subgroup. | |

| Reporting group values | Adenoid cystic carcinoma (ACC) | Non-Adenoid Cystic Carcinoma (Non ACC) | Total |
|---|---|---|---|
| Number of subjects | 46 | 52 | 98 |
| Age categorical<br>Units: Subjects | | | |
| Adults (18-64 years) | 27 | 30 | 57 |
| From 65-84 years | 19 | 22 | 41 |
| Age continuous<br>Units: years | | | |
| median | 58.5 | 62.5 | |
| full range (min-max) | 36 to 80 | 29 to 81 | - |
| Gender categorical<br>Units: Subjects | | | |
| Female | 20 | 23 | 43 |
| Male | 26 | 29 | 55 |
| ECOG<br>Units: Subjects | | | |
| PS 0 | 23 | 19 | 42 |
| PS 1 | 23 | 32 | 55 |
| PS 2 | 0 | 1 | 1 |
| Metastatic disease<br>Units: Subjects | | | |
| No | 4 | 3 | 7 |
| Yes | 42 | 49 | 91 |
| Loco-regional recurrent disease<br>Units: Subjects | | | |
| No | 35 | 34 | 69 |
| Yes | 11 | 18 | 29 |
| Primary site of cancer : Major glands<br>Units: Subjects | | | |
| No | 14 | 8 | 22 |
| Yes | 32 | 44 | 76 |
| Primary site of cancer : Minor glands<br>Units: Subjects | | | |
| No | 34 | 44 | 78 |
| Yes | 12 | 8 | 20 |

## End points

### End points reporting groups

| Reporting group title | Adenoid cystic carcinoma (ACC) |
|---|---|

Reporting group description:

Salivary Glands Carcinoma were separated in two cohorts/sub-groups: Adenoid Cystic Carcinoma (ACC) and Non-Adenoid Cystic Carcinoma (Non ACC).
In this "Arm" we reported results from the ACC subgroup.

| Reporting group title | Non-Adenoid Cystic Carcinoma (Non ACC) |
|---|---|

Reporting group description:

Salivary Glands Carcinoma were separated in two cohorts/sub-groups: Adenoid Cystic Carcinoma (ACC) and Non-Adenoid Cystic Carcinoma (Non ACC).
In this "Arm" we reported results from the Non ACC subgroup.

### Primary: Response rate at 6 months

| End point title | Response rate at 6 months[1] |
|---|---|

End point description:

The primary objective was to evaluate the non progression rate at 6 months in patients with recurrent and/or metastatic salivary gland carcinoma of the head and neck who have progressed during the 6 months period before entering the study and who were eligible for nivolumab monotherapy.
Imaging were centrally reviewed.

| End point type | Primary |
|---|---|

End point timeframe:

The primary endpoint was the non-progression rate at 6 months. Radiological assessments performed at pre-baseline (in the 6-month period before baseline), at baseline and until 6 months.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This study was not designed to compare ACC and Non-ACC population. Thus, statistical comparisons by hypothesis tests between groups were not planned.

| End point values | Adenoid cystic carcinoma (ACC) | Non-Adenoid Cystic Carcinoma (Non ACC) | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 46 | 52 | | |
| Units: percent | | | | |
| number (not applicable) | | | | |
| Response rate | 33.3 | 14 | | |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Progression-free survival

| End point title | Progression-free survival |
|---|---|

End point description:

Progression Free Survival was evaluated using Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1).

| End point type | Secondary |
|---|---|

End point timeframe:

At baseline, every 8 weeks for the first year then every 12 weeks there after untill disease progression, up to 3 years.

| **End point values** | Adenoid cystic carcinoma (ACC) | Non-Adenoid Cystic Carcinoma (Non ACC) | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 46 | 52 | | |
| Units: percent | | | | |
| median (confidence interval 95%) | 5.3 (3.2 to 5.6) | 1.8 (1.7 to 3.5) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Objective response rate

| End point title | Objective response rate |
|---|---|

End point description:

Objective response rate was defined as thepercentage of patients with a best overall response of confirmed complete response (CR) or partial response (PR). Best overall response was defined as the best response recorded between the date of first dose and the date of the initial objectively documented tumor progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

| End point type | Secondary |
|---|---|

End point timeframe:

At baseline, every 8 weeks for the first year then every 12 weeks there after untill disease progression, up to 3 years.

| **End point values** | Adenoid cystic carcinoma (ACC) | Non-Adenoid Cystic Carcinoma (Non ACC) | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 46 | 52 | | |
| Units: percent | | | | |
| median (confidence interval 95%) | 8.7 (2.4 to 20.8) | 3.8 (0.5 to 13.2) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall survival

| End point title | Overall survival |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

Overall survival was defined as the time inclusion until death of any cause, up to 3 years.

| End point values | Adenoid cystic carcinoma (ACC) | Non-Adenoid Cystic Carcinoma (Non ACC) | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 46 | 52 | | |
| Units: percent | | | | |
| median (confidence interval 95%) | 17.2 (12.5 to 40) | 11.5 (7.5 to 14.8) | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

| Adverse events information | |
|---|---|
| Timeframe for reporting adverse events: From inclusion until 30 days after end of treatment (up to 3 years). | |
| Assessment type | Systematic |

| Dictionary used | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 20 |

| Reporting groups | |
|---|---|
| Reporting group title | Adenoid Cystic Carcinoma (ACC) |
| Reporting group description: - | |
| Reporting group title | Non-Adenoid Cystic Carcinoma (Non ACC) |
| Reporting group description: - | |

| Serious adverse events | Adenoid Cystic Carcinoma (ACC) | Non-Adenoid Cystic Carcinoma (Non ACC) | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 10 / 46 (21.74%) | 15 / 52 (28.85%) | |
| number of deaths (all causes) | 26 | 32 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Investigations | | | |
| Liver function test increased | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Bladder cancer | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningioma | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tumour pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post biopsy bleeding | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Nervous system disorders | | | |
| Spinal cord compression | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Disease progression | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Oedema lower limb | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 46 (2.17%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 2 / 52 (3.85%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Erysipelas | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| **Respiratory, thoracic and mediastinal disorders** | | | |
| Acute respiratory insufficiency | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aspiration pneumonia | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Pneumothorax | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| **Endocrine disorders** | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| Musculoskeletal and connective tissue disorders | | | |
| Fasciitis | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myositis | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Epiduritis | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung infection | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Septic shock | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 46 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malnutrition | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 3 %

| **Non-serious adverse events** | Adenoid Cystic Carcinoma (ACC) | Non-Adenoid Cystic Carcinoma (Non ACC) | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 46 / 46 (100.00%) | 35 / 52 (67.31%) | |
| Investigations | | | |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 1 / 46 (2.17%) | 2 / 52 (3.85%) | |
| occurrences (all) | 1 | 2 | |
| Lipase | | | |
| subjects affected / exposed | 2 / 46 (4.35%) | 0 / 52 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Vascular disorders | | | |
| Hot flush | | | |
| subjects affected / exposed | 2 / 46 (4.35%) | 0 / 52 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Blood and lymphatic system disorders | | | |
| Eosinopenia | | | |
| subjects affected / exposed | 2 / 46 (4.35%) | 0 / 52 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 13 / 46 (28.26%) | 9 / 52 (17.31%) | |
| occurrences (all) | 13 | 9 | |
| Chest pain | | | |
| subjects affected / exposed | 2 / 46 (4.35%) | 0 / 52 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 7 / 46 (15.22%) | 2 / 52 (3.85%) | |
| occurrences (all) | 7 | 2 | |
| Dry mouth | | | |
| subjects affected / exposed | 4 / 46 (8.70%) | 2 / 52 (3.85%) | |
| occurrences (all) | 4 | 2 | |
| Nausea | | | |
| subjects affected / exposed | 4 / 46 (8.70%) | 1 / 52 (1.92%) | |
| occurrences (all) | 4 | 1 | |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|---|---|---|
| Dry skin | | | |
| subjects affected / exposed | 2 / 46 (4.35%) | 2 / 52 (3.85%) | |
| occurrences (all) | 2 | 2 | |
| Erythema | | | |
| subjects affected / exposed | 2 / 46 (4.35%) | 0 / 52 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Pruritus | | | |
| subjects affected / exposed | 5 / 46 (10.87%) | 7 / 52 (13.46%) | |
| occurrences (all) | 5 | 7 | |
| Rash | | | |
| subjects affected / exposed | 6 / 46 (13.04%) | 3 / 52 (5.77%) | |
| occurrences (all) | 6 | 3 | |
| Skin lesion | | | |
| subjects affected / exposed | 2 / 46 (4.35%) | 0 / 52 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Endocrine disorders | | | |
| Hyperthyroidism | | | |
| subjects affected / exposed | 8 / 46 (17.39%) | 0 / 52 (0.00%) | |
| occurrences (all) | 8 | 0 | |
| Hypothyroidism | | | |
| subjects affected / exposed | 5 / 46 (10.87%) | 2 / 52 (3.85%) | |
| occurrences (all) | 5 | 2 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 4 / 46 (8.70%) | 3 / 52 (5.77%) | |
| occurrences (all) | 4 | 3 | |
| Myalgia | | | |
| subjects affected / exposed | 3 / 46 (6.52%) | 2 / 52 (3.85%) | |
| occurrences (all) | 3 | 2 | |
| Infections and infestations | | | |
| Herpes zoster | | | |
| subjects affected / exposed | 2 / 46 (4.35%) | 0 / 52 (0.00%) | |
| occurrences (all) | 2 | 0 | |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported